[FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
Gene-disease associations manually curated.
DisGeNET evidence - CURATED